(PubMed) Hayflick SJ
Aug 18: Regeneron Pharmaceuticals Veopoz (pozelimab) secured FDA approval as the first and only treatment indicated specifically for CHAPLE disease, also known as CD55-deficient protein-losing enteropathy, an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms
For about four weeks, the whipworms feed on blood vessels located within the cecum of the large intestine
Visceral fat reduction from tesamorelin typically requires the full two months to become clearly visible
In healthy subjects, subcutaneous injections of GLP-2 elicit a dose-related decrease in CTX-1 (a bone resorption marker), which has sparked suggestions for the use of GLP-2 as a potential osteoporosis treatment [68]
Notably, non-synonymous mutations such as p.Ala373Ser, p.Ser398Thr, and p.Thr725Pro in the TPO gene, along with p.Ser508Leu and p.Glu727Asp in TSHR gene, were detected in these patients